| Patrick Bushard, | |
|
300 Exempla Cir, Suite 230, Lafayette, CO 80026-3397 | |
| (303) 781-4485 | |
| (720) 274-0064 |
| Full Name | Patrick Bushard |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 19 Years |
| Location | 300 Exempla Cir, Lafayette, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306998448 | NPI | - | NPPES |
| 20856865 | Medicaid | CO |
| Facility Name | Location | Facility Type |
|---|---|---|
| Good Samaritan Medical Center Llc | Lafayette, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Scl Health Medical Group - Denver Llc | 0840513552 | 414 |
News Archive
Adjusting a specific deep-brain circuit's firing frequency immediately and dramatically alters rats' forebrain activity and alertness levels, Stanford University School of Medicine investigators have shown.
An international study involving Manchester researchers has found that for previously untreated lung cancer patients with a particular genetic change, a new targeted therapy is better than standard chemotherapy.
Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Compartment Syndrome.
Political leaders, donor representatives, and medical experts on Thursday met on the sidelines of the 67th U.N. General Assembly session "to celebrate polio eradication efforts that have already reduced the incidence of the crippling and potentially fatal disease by 99 percent around the globe," the U.N. News Centre reports.
› Verified 6 days ago
| Entity Name | Good Samaritan Medical Center, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043250780 PECOS PAC ID: 7618995275 Enrollment ID: O20051102001154 |
News Archive
Adjusting a specific deep-brain circuit's firing frequency immediately and dramatically alters rats' forebrain activity and alertness levels, Stanford University School of Medicine investigators have shown.
An international study involving Manchester researchers has found that for previously untreated lung cancer patients with a particular genetic change, a new targeted therapy is better than standard chemotherapy.
Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Compartment Syndrome.
Political leaders, donor representatives, and medical experts on Thursday met on the sidelines of the 67th U.N. General Assembly session "to celebrate polio eradication efforts that have already reduced the incidence of the crippling and potentially fatal disease by 99 percent around the globe," the U.N. News Centre reports.
› Verified 6 days ago
| Entity Name | Scl Health Medical Group - Denver Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083021083 PECOS PAC ID: 0840513552 Enrollment ID: O20150106000131 |
News Archive
Adjusting a specific deep-brain circuit's firing frequency immediately and dramatically alters rats' forebrain activity and alertness levels, Stanford University School of Medicine investigators have shown.
An international study involving Manchester researchers has found that for previously untreated lung cancer patients with a particular genetic change, a new targeted therapy is better than standard chemotherapy.
Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Compartment Syndrome.
Political leaders, donor representatives, and medical experts on Thursday met on the sidelines of the 67th U.N. General Assembly session "to celebrate polio eradication efforts that have already reduced the incidence of the crippling and potentially fatal disease by 99 percent around the globe," the U.N. News Centre reports.
› Verified 6 days ago
| Entity Name | Carepoint Outpatient Blue Sky Neurology Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609247857 PECOS PAC ID: 9739485988 Enrollment ID: O20160314002170 |
News Archive
Adjusting a specific deep-brain circuit's firing frequency immediately and dramatically alters rats' forebrain activity and alertness levels, Stanford University School of Medicine investigators have shown.
An international study involving Manchester researchers has found that for previously untreated lung cancer patients with a particular genetic change, a new targeted therapy is better than standard chemotherapy.
Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Compartment Syndrome.
Political leaders, donor representatives, and medical experts on Thursday met on the sidelines of the 67th U.N. General Assembly session "to celebrate polio eradication efforts that have already reduced the incidence of the crippling and potentially fatal disease by 99 percent around the globe," the U.N. News Centre reports.
› Verified 6 days ago
| Entity Name | Carepoint Inpatient Blue Sky Neurology Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568833713 PECOS PAC ID: 9436456118 Enrollment ID: O20160323001467 |
News Archive
Adjusting a specific deep-brain circuit's firing frequency immediately and dramatically alters rats' forebrain activity and alertness levels, Stanford University School of Medicine investigators have shown.
An international study involving Manchester researchers has found that for previously untreated lung cancer patients with a particular genetic change, a new targeted therapy is better than standard chemotherapy.
Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Compartment Syndrome.
Political leaders, donor representatives, and medical experts on Thursday met on the sidelines of the 67th U.N. General Assembly session "to celebrate polio eradication efforts that have already reduced the incidence of the crippling and potentially fatal disease by 99 percent around the globe," the U.N. News Centre reports.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Patrick Bushard, Po Box 17528, Denver, CO 80217-0528 Ph: (405) 682-3303 | Patrick Bushard, 300 Exempla Cir, Suite 230, Lafayette, CO 80026-3397 Ph: (303) 781-4485 |
News Archive
Adjusting a specific deep-brain circuit's firing frequency immediately and dramatically alters rats' forebrain activity and alertness levels, Stanford University School of Medicine investigators have shown.
An international study involving Manchester researchers has found that for previously untreated lung cancer patients with a particular genetic change, a new targeted therapy is better than standard chemotherapy.
Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Compartment Syndrome.
Political leaders, donor representatives, and medical experts on Thursday met on the sidelines of the 67th U.N. General Assembly session "to celebrate polio eradication efforts that have already reduced the incidence of the crippling and potentially fatal disease by 99 percent around the globe," the U.N. News Centre reports.
› Verified 6 days ago
Anna Shapiro, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1455 Dixon Ave, Lafayette, CO 80026 Phone: 303-443-8500 | |
Dr. Stanley George Strauss, Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2383 Lavender Hill Ln, Lafayette, CO 80026 Phone: 303-604-1300 | |
Dr. Paul A Foley, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 280 Exempla Cir, Lafayette, CO 80026 Phone: 303-338-4545 | |
Katrina Marie Pack, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 300 Exempla Cir, Suite 230, Lafayette, CO 80026 Phone: 303-689-6591 Fax: 303-306-7753 | |
Eric A Haaland, Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1455 Dixon Ave, Lafayette, CO 80026 Phone: 303-443-8500 | |
Dr. Lara W Katzin, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 280 Exempla Cir, Lafayette, CO 80026 Phone: 303-338-4545 |